Medicare utilization — JEFFREY LIN (D.O.)
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| J0878 | Injection, daptomycin, 1 mg | 1,950,774 | 108 | $0 | $78,442 |
| J0121 | Injection, omadacycline, 1 mg | 105,509 | 70 | $0 | $302,084 |
| J2406 | Injection, oritavancin (kimyrsa), 10 mg | 19,080 | 110 | $0 | $619,490 |
| J2185 | Injection, meropenem, 100 mg | 8,545 | 18 | $0 | $3,626 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 6,993 | 144 | $0 | $2,818 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·